Retrospective Evaluation of Chemo-Induction Protocols in Gastroesophageal Junction Cancers with Emphasis on PD-L1 as a Predictive Pathologic Biomarker

Document Type : Original Article

Authors

1 Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Associate Professor of Radiology, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

10.22034/mphrj.2026.586292.1101
Abstract
Introduction: Gastroesophageal junction cancers show variable responses to chemo-induction, highlighting the need for predictive biomarkers. PD-L1, through its role in tumor–immune interactions, may help identify patients more likely to benefit from preoperative treatment. This study aimed to retrospectively evaluate chemo-induction outcomes in GEJ cancers with emphasis on PD-L1 as a predictive pathologic biomarker.

Material and methods: This retrospective cross-sectional study, approved by the Tabriz University of Medical Sciences Ethics Committee, evaluated 100 gastroesophageal junction cancer patients at Shahid Madani Hospital. Using accessible sampling, clinical data and PD-L1 expression were analyzed. Statistical analyses, including chi-square tests and logistic regression, were performed to identify predictors of pathological response.

Results: In 100 patients, baseline variables were comparable between the dexmedetomidine and lidocaine groups (all p > 0.05). Infusion duration, surgery time, anesthesia time, treatment completion, pathological findings, treatment response, and PD-L1 positivity did not differ significantly between groups. Only total study drug dose differed significantly (92.6 ± 18.4 µg vs. 248.3 ± 41.7 mg, p < 0.001).

Conclusion: These findings indicate that dexmedetomidine and lidocaine were associated with broadly similar perioperative, pathological, and immunohistochemical outcomes in this cohort. The absence of significant between-group differences in pathological response and PD-L1 expression suggests that neither intervention demonstrated clear superiority in influencing tumor-related postoperative characteristics.

Graphical Abstract

Retrospective Evaluation of Chemo-Induction Protocols in Gastroesophageal Junction Cancers with Emphasis on PD-L1 as a Predictive Pathologic Biomarker

Keywords

Subjects

[1]       Ahn S, Lee J, Hong M, Kim ST, Park SH, Choi MG et al (2016), FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol 29(9):1095-1103.       
[3]       Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B et al (2020) Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol 22(12):2357-2363.
[4]       Babina IS, Turner NC (2017) Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer 17(5):318-332.         
[6]       Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A et al (2016) HER2-Testung beim Magenkarzinom Ergebnisse eines deutschemark Expertentreffens.            Pathologe 37(4):361-366.
[7]       Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd et al (2016) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of american pathologists, american society for clinical pathology, and american society of clinical oncology. Arch Pathol Lab Med 140(12):1345-1363.
[8]       Beery AK, Zucker I (2011) Sex bias in neuroscience and biomedical research. Neurosis Biobehav Rev 35(3):565-572.   
[9]       Betts G, Valentine H, Pritchard S, Swindell R, Williams V, Morgan S et al (2014) FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation. Virchows Arch 464(2):145-156. 
[10]    Rebout, F. (2025). Ultrasound of the skeletal and muscular system. Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research, 1(1), 19-25.
[11]    Zbuzant, M. (2025). Fetal movement in the anterior placenta. Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research, 1(1), 26-34.
[13]    Brous, A. (2025). Essential of Muskelesketal Ultrasound. Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research, 1(1), 12-18.
[14]   Bolandi N, Derakhshani A, Hemmat N, Baghbanzadeh A, Asadzadeh Z, Afrashteh Nour M et al (2021) The positive and negative immunoregulatory role of b7 family: promising novel targets in gastric cancer treatment. Int J Mol Sci.
[15]    Brusselaers N, Maret-Ouda J, Konings P, El-Serag HB, Lagergren J (2017) Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer 140(7):1693-1699.
[16]    Cancer Genome Atlas Research N (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-209.
[17]    Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C (2002) Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 15(8):831-837.          
[18]    Albuzyad, S. S. and Jawad, M. K. (2025). A Systematic Review of Radiology and Radio Oncology Evaluations in Patients with Thoracic and Pelvic Cancers based on Radiological Images. Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research, 1(1), 1-11.
[19]    NazarI, M. Akhlaghi, F. Pourfathi Nematabad, H. (2025), Comparison of Postoperative nausea and vomiting prevalence in patients with routine NPO and NPO with clear fluids 2 hours before cataract surgery, Journal of Advanced in Medicinal, Pharmaceutical and Biomedical Research, 1, 132-139